Healthcare

Daily Healthcare: KRI (KRI MK): Continued Capacity Expansion to Meet Solid Demand and more

In this briefing:

  1. KRI (KRI MK): Continued Capacity Expansion to Meet Solid Demand
  2. Kalbe Farma (KLBF IJ): Navigating Through the New Pharma Dynamics

1. KRI (KRI MK): Continued Capacity Expansion to Meet Solid Demand

  • More attractive to analysts, low price-to-sales, and low correlation with Western stock markets relative to its sector
  • To meet strong demand, KRI recently commissioned Plant 17, which increased capacity by 1.5bn. Upcoming Plants 18 and 19 to commission in 2019 should add another 5.5bn or a 20% capacity increase
  • High barriers to entry for medical gloves due to stringent compliance to regulatory requirement aids KPI market shares
  • Trades above ASEAN Health Care at 19CE* 4.1x PB, in line with offering a better ROE
  • Risks: Sudden jump in raw materials prices

* Consensus Estimates

2. Kalbe Farma (KLBF IJ): Navigating Through the New Pharma Dynamics

Klbf%20oncology%20and%20biosimilar

The healthcare industry in Indonesia has undergone a massive change since the introduction of the National Health Insurance (JKN) in 2014. Although the program allows for better healthcare access for over 200mn Indonesians, the industry dynamics have shifted and Kalbe Farma (KLBF IJ) is one of the companies that has been on the losing side during this adjustment period.

With the Health and Social Security (BPJS) deficit forecast to grow to IDR16t by end of 2018, and with a continuing roll out of coverage to 250mn people by end of 2019, all parties in the healthcare industry are expected to continue subsidizing the program.  Hospitals and drug manufacturers have had to cope with relatively flat pricing from the INA-CBG (reimbursement) tariff since 2014, despite cost pressures stemming from the currency depreciation and inflation. KLBF has reported declines in its overall pharmaceutical margin, as well as low growth rates for its licensed and OTC (over the counter) drugs over the past five years.

Our recent meeting with the company revealed that to mitigate the JKN impact, KLBF has launched several strategies, including expanding into niche specialty products such as oncology and biosimilar drugs, as well as preventive and herbal supplements. We are also at a tipping point where KLBF’s non-OTC consumer health and nutritionals revenues are finally larger than the pharmaceutical revenues for the first time. In this insight, we will discuss whether the worst is already behind us, and if it is now time to take another look at the stock. 

Get Straight to the Source on Smartkarma

Smartkarma supports the world’s leading investors with high-quality, timely, and actionable Insights. Subscribe now for unlimited access, or request a demo below.